Palitra Bio tests candidate treatments directly against a patient's own tumour cells, with a PhD data team and an MD tumour board turning the results into a personalised treatment plan.
Palitra Bio offers what it calls maximalist functional testing: rational therapeutic options are tested against the patient's own tumour cells, matched to malignancy, stage and goals of care, and synthesised by a data team and a medical tumour board into guidance for the treating clinicians. Its chief executive brings fifteen years at the intersection of cancer biology and translational research. It is an Even One Ventures portfolio company.
Shares Even One Ventures, Functional (ex vivo) drug testing and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures, Functional (ex vivo) drug testing and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.
Shares Even One Ventures and the tags startup, evenone-portfolio, oncology.